Benlysta treats an immune system disease, lupus. Can increase your chance of getting an infection. Tell your doctor if you notice any signs of infection such as a fever.
Benlysta is a prescription medicine that is used with other medicines to treat lupus. Benlysta is in a class of medications called monoclonal antibodies and works by affecting the immune system by blocking the activity of a certain protein in people with lupus.
Patient Ratings for Benlysta
How was your experience with Benlysta?
Benlysta Cautionary Labels
Uses of Benlysta
Benlysta is a prescription medicine used to treat adults with active systemic lupus erythematosus (SLE or lupus) who are receiving other lupus medicines.
Benlysta Drug Class
Benlysta is part of the drug class:
Side Effects of Benlysta
Benlysta can cause serious side effects. See “Drug Precautions”
The most common side effects of Benlysta include:
- stuffy or runny nose
- sore throat
- cough (bronchitis)
- trouble sleeping
- leg or arm pain
- headache (migraine)
- urinary tract infection
- decreased white blood cell count (leukopenia)
- stomach pain
Tell your healthcare provider if you have any side effect that bothers you or that does not go away.
These are not all the possible side effects of Benlysta . Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Do not receive Benlysta if you are allergic to Benlysta or any of the ingredients in Benlysta.
- pain or burning with urination
- urinating often
- bloody diarrhea
- coughing up mucus
- chest discomfort or pain
- shortness of breath
- cold sweats
- discomfort in other areas of the upper body
- thoughts of suicide or dying
- attempt to commit suicide
- trouble sleeping (insomnia)
- new or worse anxiety
- new or worse depression
- acting on dangerous impulses
- other unusual changes in your behavior or mood
- thoughts of hurting yourself or others
4. Cancer. Benlysta may reduce the activity of your immune system. Medicines that affect the immune system may increase your risk of certain cancers.
5. Allergic (hypersensitivity) and infusion reactions. Serious allergic or infusion reactions can happen on the day of or the day after receiving Benlysta and may cause death. Tell your healthcare provider right away if you have any of the following symptoms of an allergic or infusion reaction:
- swelling of the face, lips, mouth, tongue, or throat
- trouble breathing
- low blood pressure
- dizziness or fainting
- skin rash, redness, or swelling
Benlysta Food Interactions
Medicines can interact with certain foods. In some cases, this may be harmful and your doctor may advise you to avoid certain foods. In the case of Benlysta there are no specific foods that you must exclude from your diet when receiving Benlysta.
Before you receive Benlysta, tell your healthcare provider if you:
- think you have an infection or have infections that keep coming back. You should not receive Benlysta if you have an infection unless your healthcare provider tells you to. See “Drug Precautions”.
- have or have had mental health problems such as depression or thoughts of suicide
- have recently received a vaccination or if you think you may need a vaccination. If you are receiving Benlysta, you should not receive live vaccines.
- are allergic to other medicines
- are receiving other biologic medicines, monoclonal antibodies or IV infusions of cyclophosphamide (Cytoxan)
- have or have had any type of cancer
- have any other medical conditions
- are pregnant or plan to become pregnant. It is not known if Benlysta will harm your unborn baby. Tell your healthcare provider if you become pregnant during your treatment with Benlysta.
- If you become pregnant while receiving Benlysta , talk to your healthcare provider about enrolling in the pregnancy registry. You can enroll in this registry by calling 1-877-681-6296. The purpose of this registry is to monitor the health of you and your baby.
- are breastfeeding or plan to breastfeed. It is not known if Benlysta passes into your breast milk. You and your healthcare provider should decide if you will receive Benlysta or breastfeed. You should not do both.
Benlysta and Pregnancy
The FDA categorizes medications based on safety for use during pregnancy. Five categories - A, B, C, D, and X, are used to classify the possible risks to an unborn baby when a medication is taken during pregnancy.
This medication falls into category C. Tell your healthcare provider if you are pregnant or plan to become pregnant. It is not known if Benlysta will harm your unborn baby. Tell your healthcare provider if you become pregnant during your treatment with Benlysta.
- If you become pregnant while receiving Benlysta, talk to your healthcare provider about enrolling in the Benlysta pregnancy registry. You can enroll in this registry by calling 1-877-681-6296. The purpose of this registry is to monitor the health of you and your baby.
Benlysta and Lactation
Tell your healthcare provider if you are breastfeeding or plan to breastfeed. It is not known if Benlysta passes into your breast milk. You and your healthcare provider should decide if you will receive Benlysta or breastfeed. You should not do both.
- You will be given Benlysta by a healthcare provider through a needle placed in a vein (IV infusion). It takes about 1 hour to give you the full dose of Benlysta.
- Your healthcare provider will tell you how often you should receive Benlysta.
- Your healthcare provider may give you medicines before you receive Benlysta to help reduce your chance of having a reaction. A healthcare provider will watch you closely while you are receiving Benlysta and after your infusion for signs of a reaction.
Take this medication exactly as prescribed by your doctor.
The dose your doctor recommends may be based on your weight.
The recommended dose of Benlysta is 10 mg/kg at 2-week intervals for the first 3 doses and at 4-week intervals thereafter.
If Benlysta is administered by a healthcare provider in a medical setting, it is unlikely that an overdose will occur. However, if overdose is suspected, seek emergency medical attention.